Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EB9V | ISIN: CA60256C1086 | Ticker-Symbol: WF6
München
22.11.24
15:33 Uhr
0,011 Euro
+0,002
+19,57 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MINDBIO THERAPEUTICS CORP Chart 1 Jahr
5-Tage-Chart
MINDBIO THERAPEUTICS CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,0110,02013:05

Aktuelle News zur MINDBIO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.10.Mindbio Therapeutics Corp: Mindbio sees 72% drop in depression 6M after treatment12
MINDBIO THERAPEUTICS Aktie jetzt für 0€ handeln
29.10.MindBio Therapeutics: MindBio Reports a 72% Reduction in Severity of Depression Sustained Six Months After Treatment in Clinical Trials2
24.10.Mindbio Therapeutics Corp: Mindbio begins dosing 20th patient in MB22001 trial3
24.10.MindBio Therapeutics: Mindbio Announces Clinical Trial Milestone In Phase 2B Microdosing Trials Targeting Existential Distress, Depression & Anxiety In Advanced Stage Cancer3
22.10.Mindbio Therapeutics Corp: Mindbio completes trial post-treatment milestone10
22.10.MindBio Therapeutics: MindBio Completes Final Post Treatment Milestone in Phase 2A Microdosing Depression Clinical Trial. Results to be Reported in the Coming Fortnight2
16.10.Mindbio Therapeutics Corp: Mindbio arranges $200,000 private placement3
16.10.MindBio Therapeutics: MindBio Announces Proposed Issuance of Listed Securities3
08.10.Mindbio Therapeutics Corp: Mindbio hits 12 months of shelf stability for MB2200110
08.10.MindBio Therapeutics: MindBio Develops Long Term Shelf-Stable Microdosing Formulation and is Progressing in Multiple Phase 2B Clinical Trials3
23.09.Mindbio Therapeutics Corp: Mindbio enrols 25th participant in MB22001 trial2
23.09.MindBio Therapeutics Enrols 25th Participant into Landmark Take-Home Microdosing Depression Trial4
29.08.MindBio advances world-first psychedelic microdosing clinical trials3
29.08.MindBio Therapeutics: MindBio CEO Provides Video Update to Shareholders on Progress of World First, Government Approved Microdosing Clinical Trials1
19.08.Mindbio Therapeutics Corp: Mindbio Therapeutics reviews MB22001 testing data3
19.08.MindBio Therapeutics: MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials374Three months post cessation of an 8-week course of microdosing treatment, the antidepressant response is sustained with a 62.8% reduction in depressive symptoms. VANCOUVER, BC / ACCESSWIRE / August...
► Artikel lesen
01.08.Mindbio Therapeutics Corp: Mindbio appoints Haywood Securities as adviser5
01.08.MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory371VANCOUVER, BC / ACCESSWIRE / August 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical company in psychiatric medicine development...
► Artikel lesen
08.07.Mindbio Therapeutics Corp: Mindbio to start dosing in MB22001 phase 2B trial11
20.06.Mindbio Therapeutics Corp: Mindbio says MB22001 shows antidepressant response10
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1